The multiple sclerosis degradome: Enzymatic cascades in development and progression of central nervous system inflammatory disease

Current Topics in Microbiology and Immunology

Volumn 318, Issue , 2008, Pages 133-175

  Scarisbrick, I A ^a  

^a MAYO GRADUATE SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ASPARTIC PROTEINASE; CALPAIN; CASPASE; CATHEPSIN; CYSTEINE PROTEINASE; DISINTEGRIN; ELASTASE; MATRIX METALLOPROTEINASE; METALLOPROTEINASE; PHLOGENZYM; PLASMINOGEN ACTIVATOR; PRALNACASAN; PROTEINASE; SERINE PROTEINASE; THREONINE; THROMBIN; TISSUE KALLIKREIN;

CENTRAL NERVOUS SYSTEM DISEASE; COMPLEMENT ACTIVATION; DISEASE ACTIVITY; DISEASE COURSE; ENZYME ACTIVITY; HUMAN; IMMUNOMODULATION; IMMUNOREACTIVITY; MULTIPLE SCLEROSIS; NERVE DEGENERATION; NERVOUS SYSTEM INFLAMMATION; NEUROTOXICITY; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; REVIEW; ANIMAL; ENZYMOLOGY; IMMUNOLOGY; INFLAMMATION; METABOLISM; PATHOPHYSIOLOGY;

ANIMALS; CENTRAL NERVOUS SYSTEM DISEASES; CYSTEINE ENDOPEPTIDASES; ENDOPEPTIDASES; HUMANS; INFLAMMATION; METALLOPROTEASES; SERINE ENDOPEPTIDASES;

EID: 39549110822     PISSN: 0070217X     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-3-540-73677-6_6     Document Type: Review

References (304)

1. Abraham M, Shapiro S, Lahat N, Miller A (2002) The role of IL-18 and IL-12 in the modulation of matrix metalloproteinases and their tissue inhibitors in monocytic cells. Int Immunol 14:1449-1457
2. Akassoglou K, Kombrinck KW, Degen JL, Strickland S (2000) Tissue plasminogen activator-mediated fibrinolysis protects against axonal degeneration and demyelination after sciatic nerve injury. J Cell Biol 149:1157-1166
3. Akassoglou K, Adams RA, Bauer J, Mercado P, Tseveleki V, Lassmann H, Probert L, Strickland S (2004) Fibrin depletion decreases inflammation and delays the onset of demyelination in a tumor necrosis factor transgenic mouse model for multiple sclerosis. Proc Natl Acad Sci USA 101:6698-6703
4. Akenami FO, Koskiniemi M, Farkkila M, Vaheri A (1997) Cerebrospinal fluid plasminogen activator inhibitor-1 in patients with neurological disease. J Clin Pathol 50:157-160
5. Angelo PF, Lima AR, Alves FM, Blaber SI, Scarisbrick IA, Blaber M, Juliano L, Juliano MA (2006) Substrate specificity of human kallikrein 6: salt and glycosaminoglycan activation effects. J Biol Chem 281:3116-3126
6. Anthony DC, Ferguson B, Matyzak MK, Miller KM, Esiri MM, Perry VH (1997) Differential matrix metalloproteinase expression in cases of multiple sclerosis and stroke. Neuropathol Appl Neurobiol 23:406-415
7. Balabanov R, Lisak D, Beaumont T, Lisak RP, Dore-Duffy P (2001) Expression of urokinase plasminogen activator receptor on monocytes from patients with relapsing-remitting multiple sclerosis: effect of glatiramer acetate (copolymer 1). Clin Diagn Lab Immunol 8:1196-1203
8. Balaji KN, Schaschke N, Machleidt W, Catalfamo M, Henkart PA (2002) Surface cathepsin B protects cytotoxic lymphocytes from self-destruction after degranulation. J Exp Med 196:493-503
9. Bando Y, Ito S, Nagai Y, Terayama R, Kishibe M, Jiang YP, Mitrovic B, Takahashi T, Yoshida S (2006) Implications of protease M/neurosin in myelination during experimental demyelination and remyelination. Neurosci Lett 405:175-180
10. Banik NL, McAlhaney WW, Hogan EL (1985) Calcium-stimulated proteolysis in myelin: evidence for a Ca2+-activated neutral proteinase associated with purified myelin of rat CNS. J Neurochem 45:581-588
11. Banik NL (1992) Pathogenesis of myelin breakdown in demyelinating diseases: role of proteolytic enzymes. Crit Rev Neurobiol 6:257-271
12. Baramova EN, Bajou K, Remacle A, L'Hoir C, Krell HW, Weidle UH, Noel A, Foidart JM (1997) Involvement of PA/plasmin system in the processing of pro-MMP-9 and in the second step of pro-MMP-2 activation. FEBS Lett 405:157-162
13. Barnett MH, Prineas JW (2004) Relapsing and remitting multiple sclerosis: pathology of the newly forming lesion. Ann Neurol 55:458-468
14. Bar-Or A, Nuttall RK, Duddy M, Alter A, Kim HJ, Ifergan I, Pennington C, Bourgoin P, Edwards DR, Yong VW (2003) Analyses of all matrix metalloproteinase members in leukocytes emphasize monocytes as major inflammatory mediators in multiple sclerosis. Brain 126:2738-2749
15. Bates IR, Boggs JM, Feix JB, Harauz G (2003) Membrane-anchoring and charge effects in the interaction of myelin basic protein with lipid bilayers studied by site-directed spin labeling. J Biol Chem 278:29041-29047
16. Baumhackl U, Kappos L, Radue EW, Freitag P, Guseo A, Daumer M, Mertin J (2005) A randomized, double-blind, placebo-controlled study of oral hydrolytic enzymes in relapsing multiple sclerosis. Mult Scler 11:166-168
17. Beers C, Honey K, Fink S, Forbush K, Rudensky A (2003) Differential regulation of cathepsin S and cathepsin L in interferon gamma-treated macrophages. J Exp Med 197:169-179
18. Beilin O, Karussis DM, Korczyn AD, Gurwitz D, Aronovich R, Hantai D, Grigoriadis N, Mizrachi-Kol R, Chapman J (2005) Increased thrombin inhibition in experimental autoimmune encephalomyelitis. J Neurosci Res 798:351-359
19. Benjamins JA, Nedelkoska L, George EB (2003) Protection of mature oligodendrocytes by inhibitors of caspases and calpains. Neurochem Res 28:143-152
20. Berahovich RD, Miao Z, Wang Y, Premack B, Howard MC, Schall TJ (2005) Proteolytic activation of alternative CCR1 ligands in inflammation. J Immunol 174:7341-7351
21. Bernett MJ, Blaber SI, Scarisbrick IA, Dhanarajan P, Thompson SM, Blaber M (2002) Crystal structure and biochemical characterization of human kallikrein 6 reveals a trypsin-like kallikrein is expressed in the central nervous system. J Biol Chem 277:24562-24570
22. Bever CT Jr, Panitch HS, Johnson KP (1994) Increased cathepsin B activity in peripheral blood mononuclear cells of multiple sclerosis patients. Neurology 44:745-748
23. Bever CT Jr, Garver DW (1995) Increased cathepsin B activity in multiple sclerosis brain. J Neurol Sci 131:71-73
24. Bjartmar C, Kinkel RP, Kidd G, Rudick RA, Trapp BD (2001) Axonal loss in normal-appearing white matter in a patient with acute MS. Neurology 57:1248-1252
25. Blaber S, Heysook Y, Scarisbrick IA, Juliani L, Blaber M (2007) The autolytic regulation of human kallkrein 6. Biochemistry, in press
26. Blaber SI, Scarisbrick IA, Bernett MJ, Dhanarajan P, Seavy MA, Jin Y, Schwartz MA, Rodriguez M, Blaber M (2002) Enzymatic properties of rat myelencephalon specific protease. Biochemistry 41:1165-1173
27. Blaber SI, Ciric B, Christophi GP, Bernett MJ, Blaber M, Rodriguez M, Scarisbrick IA (2004) Targeting kallikrein 6-proteolysis attenuates CNS inflammatory disease. FASEB J 19:920-922
28. Bo L, Vedeler CA, Nyland H, Trapp BD, Mork SJ (2003) Intracortical multiple sclerosis lesions are not associated with increased lymphocyte infiltration. Mult Scler 9:323-331
29. Boehme DH, Marks N (1979) Mitigation of experimental allergic encephalomyelitis by cathepsin D inhibition. Adv Exp Med Biol 121B:317-323
30. Borgono CA, Miacovos MP, Diamandis EP (2004) Human tissue kallikreins: physiologic roles and applications in cancer. Mol Cancer Res 2:257-280
31. Brundula V, Rewcastle NB, Metz LM, Bernard CC, Yong VW (2002) Targeting leukocyte MMPs and transmigration: minocycline as a potential therapy for multiple sclerosis. Brain 125:1297-1308
32. Busso N, Frasnelli M, Feifel R, Cenni B, Steinhoff M, Hamilton J, So A (2007) Evaluation of protease-activated receptor 2 in murine models of arthritis. Arthritis Rheum 56:101-107
33. Califano F, Giovanniello T, Pantone P, Campana E, Parlapiano C, Alegiani F, Vincentelli GM, Turchetti P (2000) Clinical importance of thrombomodulin serum levels. Eur Rev Med Pharmacol Sci 4:59-66
34. Cammer W, Bloom BR, Norton WT, Gordon S (1978) Degradation of basic protein in myelin by neutral proteases secreted by stimulated macrophages: a possible mechanism of inflammatory demyelination. Proc Natl Acad Sci USA 75:1554-1558
35. Cao L, Goodin R, Wood D, Moscarello MA, Whitaker JN (1999) Rapid release and unusual stability of immunodominant peptide 45-89 from citrullinated myelin basic protein. Biochemistry 38:6157-6163
36. Cassim B, Mody G, Bhoola KD (2002) Kallikrein cascade and cytokines in inflammed joints. Pharmacol Ther 94:1-34
37. Centonze D, Napolitano M, Saulle E, Gubellini P, Picconi B, Martorana A, Pisani A, Gulino A, Bernardi G, Calabresi P (2002) Tissue plasminogen activator is required for corticostriatal long-term potentiation. Eur J Neurosci 16:713-721
38. Cerretti DP, Kozlosky CJ, Mosley B, Nelson N, Van Ness K, Greenstreet TA, March CJ, Kronheim SR, Druck T, Cannizzaro LA et al (1992) Molecular cloning of the interleukin-1 beta converting enzyme. Science 256:97-100
39. Chabas D, Baranzini SE, Mitchell D, Bernard CC, Rittling SR, Denhardt DT, Sobel RA, Lock C, Karpuj M, Pedotti R, Heller R, Oksenberg JR, Steinman L (2001) The influence of the proinflammatory cytokine, osteopontin, on autoimmune demyelinating disease. Science 294:1731-1735
40. Chandler S, Coates R, Gearing A, Lury J, Wells G, Bone E (1995) Matrix metalloproteinases degrade myelin basic protein. Neurosci Lett 201:223-226
41. Chandler S, Cossins J, Lury J, Wells G (1996) Macrophage metalloelastase degrades matrix and myelin proteins and processes a tumour necrosis factor-alpha fusion protein. Biochem Biophys Res Commun 228:421-429
42. Chang C, Werb Z (2001) The many faces of metalloproteases: cell growth, invasion, angiogenesis and metastasis. Trends Cell Biol 11:S37-S43
43. Chapman J (2006) Thrombin in inflammatory brain diseases. Autoimmun Rev 5:528-531
44. Chou YK, Burrows GG, LaTocha D, Wang C, Subramanian S, Bourdette DN, Vandenbark AA (2004) CD4 T-cell epitopes of human alpha B-crystallin. J Neurosci Res 75:516-523
45. Christophi GP, Isackson PJ, Blaber SI, Blaber M, Rodriguez M, Scarisbrick IA (2004) Distinct promoters regulate tissue-specific and differential expression of kallikrein 6 in CNS demyelinating disease. J Neurochem 91:1439-1449
46. Cirino G, Cicala C, Bucci MR, Sorrentino L, Maraganore JM, Stone SR (1996) Thrombin functions as an inflammatory mediator through activation of its receptor. J Exp Med 183:821-827
47. Claudio L, Raine CS, Brosnan CF (1995) Evidence of persistent blood brain barrier abnormalities in chromic-progressive multiple sclerosis. Acta Neuropathol (Berl) 90:228-238
48. Clements JM, Cossins JA, Wells GM, Corkill DJ, Helfrich K, Wood LM, Pigott R, Stabler G, Ward GA, Gearing AJ, Miller KM (1997) Matrix metalloproteinase expression during experimental autoimmune encephalomyelitis and effects of a combined matrix metalloproteinase and tumour necrosis factor-alpha inhibitor. J Neuroimmunol 74:85-94
49. Colton CA, Keri JE, Chen WT, Monsky WL (1993) Protease production by cultured microglia: substrate gel analysis and immobilized matrix degradation. J Neurosci Res 35: 297-304
50. Comabella M, Romera C, Camina M, Perkal H, Moro MA, Leza JC, Lizasoain I, Castillo M, Montalban X (2006) TNF-alpha converting enzyme (TACE) protein expression in different clinical subtypes of multiple sclerosis. J Neurol 253:701-706
51. Cossins JA, Clements JM, Ford J, Miller KM, Pigott R, Vos W, Van der Valk P, De Groot CJ (1997) Enhanced expression of MMP-7 and MMP-9 in demyelinating multiple sclerosis lesions. Acta Neuropathol (Berl) 94:590-598
52. Coughlin SR (2005) Protease-activated receptors in hemostasis, thrombosis and vascular biology. J Thromb Haemost 3:1800-1814
53. Csernok E, Ai M, Gross WL, Wicklein D, Petersen A, Lindner B, Lamprecht P, Holle JU, Hellmich B (2006) Wegener autoantigen induces maturation of dendritic cells and licenses them for Th1 priming via the protease-activated receptor-2 pathway. Blood 107:4440-4448
54. Cunningham MA, Rondeau E, Chen X, Coughlin SR, Holdsworth SR, Tipping PG (2000) Protease-activated receptor 1 mediates thrombin-dependent, cell-mediated renal inflammation in crescentic glomerulonephritis. J Exp Med 191:455-462
55. Cuzner ML, Gveric D, Strand C, Loughlin AJ, Paemen L, Opdenakker G, Newcombe J (1996) The expression of tissue-type plasminogen activator, matrix metalloproteases and endogenous inhibitors in the central nervous system in multiple sclerosis: comparison of stages in lesion evolution. J Neuropath Exp Neurol 55:1194-1204
56. Davie CA, Barker GJ, Thompson AJ, Tofts PS, McDonald WI, Miller DH (1997) 1H magnetic resonance spectroscopy of chronic cerebral white matter lesions and normal appearing white matter in multiple sclerosis. J Neurol Neurosurg Psychiatry 63:736-742
57. Davies B, Kearns IR, Ure J, Davies CH, Lathe R (2001) Loss of hippocampal serine protease BSP1/neuropsin predisposes to global seizure activity. J Neurosci 21:6993-7000
58. De La Luz Sierra M, Yang F, Narazaki M, Salvucci O, Davis D, Yarchoan R, Zhang HH, Fales H, Tosato G (2004) Differential processing of stromal-derived factor-1alpha and stromal-derived factor-1beta explains functional diversity. Blood 103:2452-2459
59. del Zoppo GJ, Milner R (2006) Integrin-matrix interactions in the cerebral microvasculature. Arterioscler Thromb Vasc Biol 26:1966-1975
60. Deshpande RV, Goust JM, Hogan EL, Banik NL (1995) Calpain secreted by activated human lymphoid cells degrades myelin. J Neurosci Res 42:259-265
61. Dhib-Jalbut S (2002) Mechanisms of action of interferons and glatiramer acetate in multiple sclerosis. Neurology 58:S3-S9.
62. Diaz-Sanchez M, Williams K, DeLuca GC, Esiri MM (2006) Protein co-expression with axonal injury in multiple sclerosis plaques. Acta Neuropathol (Berl) 111:289-299
63. Dietsch GN, Hinrichs DJ (1991) Mast cell proteases liberate stable encephalitogenic fragments from intact myelin. Cell Immunol 135:541-548
64. Dihanich M, Kaser M, Reinhard E, Cunningham D, Monard D (1991) Prothrombin mRNA is expressed by cells of the nervous system. Neuron 6:575-581
65. Dinarello CA, Fantuzzi G (2003) Interleukin-18 and host defense against infection. J Infect Dis 187 Suppl 2:S370-S384
66. Donovan FM, Cunningham DD (1998) Signaling pathways involved in thrombin-induced cell protection. J Biol Chem 273:12746-12752
67. D'Souza CA, Mak B, Moscarello MA (2002) The up-regulation of stromelysin-1 (MMP-3) in a spontaneously demyelinating transgenic mouse precedes onset of disease. J Biol Chem 277:13589-13596
68. Dubois B, Masure S, Hurtenbach U, Paemen L, Heremans H, van den Oord J, Sciot R, Meinhardt T, Hammerling G, Opdenakker G, Arnold B (1999) Resistance of young gelatinase B-deficient mice to experimental autoimmune encephalomyelitis and necrotizing tail lesions. J Clin Invest 104:1507-1515
69. Earnshaw WC (1999) Apoptosis. A cellular poison cupboard. Nature 397:387-389
70. East E, Baker D, Pryce G, Lijnen HR, Cuzner ML, Gveric D (2005) A role for the plasminogen activator system in inflammation and neurodegeneration in the central nervous system during experimental allergic encephalomyelitis. Am J Pathol 167:545-554
71. Ehlert JE, Gerdes J, Flad HD, Brandt E (1998) Novel C-terminally truncated isoforms of the CXC chemokine beta-thromboglobulin and their impact on neutrophil functions. J Immunol 161:4975-4982
72. Elliott PJ, Pien CS, McCormack TA, Chapman ID, Adams J (1999) Proteasome inhibition: A novel mechanism to combat asthma. J Allergy Clin Immunol 104:294-300
73. Esparza J, Kruse M, Lee J, Michaud M, Madri JA (2004) MMP-2 null mice exhibit an early onset and severe experimental autoimmune encephalomyelitis due to an increase in MMP-9 expression and activity. FASEB J 18:1682-1691
74. Fadeel B, Kagan VE (2003) Apoptosis and macrophage clearance of neutrophils: regulation by reactive oxygen species. Redox Rep 8:143-150
75. Feinberg MW, Jain MK, Werner F, Sibinga NE, Wiesel P, Wang H, Topper JN, Perrella MA, Lee ME (2000) Transforming growth factor-beta 1 inhibits cytokine-mediated induction of human metalloelastase in macrophages. J Biol Chem 275:25766-25773
76. Ferguson B, Matyszak MK, Esiri MM, Perry VH (1997) Axonal damage in acute multiple sclerosis lesions. Brain 120:393-399
77. Festoff BW, D'Andrea MR, Citron BA, Salcedo RM, Smirnova IV, Andrade-Gordon P (2000) Motor neuron cell death in wobbler mutant mice follows overexpression of the G-protein-coupled, protease-activated receptor for thrombin. Mol Med 6:410-429
78. Franciotta D, Martino G, Zardini E, Furlan R, Bergamaschi R, Gironi M, Bergami A, Angelini G, De Benedetti F, Pignatti P, Moscato G, Cosi V (2002) Caspase-1 levels in biological fluids from patients with multiple sclerosis and from patients with other neurological and non-neurological diseases. Eur Cytokine Netw 13:99-103
79. Fridman R, Toth M, Pena D, Mobashery S (1995) Activation of progelatinase B (MMP-9) by gelatinase A (MMP-2). Cancer Res 55:2548-2555
80. Friedmann I, Hauben E, Yoles E, Kardash L, Schwartz M (2001) T cell-mediated neuroprotection involves antithrombin activity. J Neuroimmunol 121:12-21
81. Friedmann I, Yoles E, Schwartz M (2001) Thrombin attenuation is neuroprotective in the injured rat optic nerve. J Neurochem 76:641-649
82. Frigerio S, Ariano C, Bernardi G, Ciusani E, Massa G, La Mantia L, Salmaggi A (1998) Cerebrospinal fluid thrombomodulin and sVCAM-1 in different clinical stages of multiple sclerosis patients. J Neuroimmunol 87:88-93
83. Furlan R, Filippi M, Bergami A, Rocca MA, Martinelli V, Poliani PL, Grimaldi LM, Desina G, Comi G, Martino G (1999) Peripheral levels of caspase-1 mRNA correlate with disease activity in patients with multiple sclerosis; a preliminary study. J Neurol Neurosurg Psychiatry 67:785-788
84. Furlan R, Martino G, Galbiati F, Poliani PL, Smiroldo S, Bergami A, Desina G, Comi G, Flavell R, Su MS, Adorini L (1999) Caspase-1 regulates the inflammatory process leading to autoimmune demyelination. J Immunol 163:2403-2409
85. Garton KJ, Gough PJ, Philalay J, Wille PT, Blobel CP, Whitehead RH, Dempsey PJ, Raines EW (2003) Stimulated shedding of vascular cell adhesion molecule 1 (VCAM-1) is mediated by tumor necrosis factor-alpha-converting enzyme (ADAM 17). J Biol Chem 278:37459-37464
86. Gearing AJ, Beckett P, Christodoulou M, Churchill M, Clements JM, Crimmin M, Davidson AH, Drummond AH, Galloway WA, Gilbert R et al (1995) Matrix metalloproteinases and processing of pro-TNF-alpha. J Leukoc Biol 57:774-777
87. Gijbels K, Masure S, Carton H, Opdenakker G (1992) Gelatinase in cerebrospinal fluid of patients with multiple sclerosis and other inflammatory neurological disorders. J Neuroimmunol 41:29-34
88. Gijbels K, Galardy RE, Steinman L (1994) Reversal of experimental allergic encephalomyelitis with a hydroxamate inhibitor of matrix metalloproteases. J Clin Invest 94:2177-2182
89. Goetzl EJ, Banda MJ, Leppert D (1996) Matrix metalloproteinases in immunity. J Immunol 156:1-4
90. Gottschall PE, Deb S (1996) Regulation of matrix metalloproteinase expressions in astrocytes, microglia and neurons. Neuroimmunomodulation 3:69-75
91. Gough PJ, Garton KJ, Wille PT, Rychlewski M, Dempsey PJ, Raines EW (2004) A disintegrin and metalloproteinase 10-mediated cleavage and shedding regulates the cell surface expression of CXC chemokine ligand 16. J Immunol 172:3678-3685
92. Gran B, Tabibzadeh N, Martin A, Ventura ES, Ware JH, Zhang G-X, Parr JL, Kennedy AR, Rostami AM (2006) The protease inhibitor, Bowman-Birk inhibitor, suppresses experimental autoimmune encephalomyelitis: a potential oral therapy for multiple sclerosis. Mult Scler 12:688-697
93. Greiner A, Lautwein A, Overkleeft HS, Weber E, Driessen C (2003) Activity and subcellular distribution of cathepsins in primary human monocytes. J Leukoc Biol 73:235-242
94. Gronski TJ Jr, Martin RL, Kobayashi DK, Walsh BC, Holman MC, Huber M, Van Wart HE, Shapiro SD (1997) Hydrolysis of a broad spectrum of extracellular matrix proteins by human macrophage elastase. J Biol Chem 272:12189-12194
95. Gu C, Casaccia-Bonnefil P, Srinivasan A, Chao MV (1999) Oligodendrocyte apoptosis mediated by caspase activation. J Neurosci 19:3043-3049
96. Gu Z, Kaul M, Yan B, Kridel SJ, Cui J, Strongin A, Smith JW, Liddington RC, Lipton SA (2002) S-nitrosylation of matrix metalloproteinases: signaling pathway to neuronal cell death. Science 297:1186-1190
97. Gurney KJ, Estrada EY, Rosenberg GA (2006) Blood-brain barrier disruption by stromelysin-1 facilitates neutrophil infiltration in neuroinflammation. Neurobiol Dis 23:87-96
98. Gurwitz D, Cunningham DD (1990) Neurite outgrowth activity of protease nexin-1 on neuroblastoma cells requires thrombin inhibition. J Cell Physiol 142:155-162
99. Gveric D, Hanemaaijer R, Newcombe J, van Lent NA, Sier CF, Cuzner ML (2001) Plasminogen activators in multiple sclerosis lesions: implications for the inflammatory response and axonal damage. Brain 124:1978-1988
100. Gveric D, Herrera BM, Cuzner ML (2005) tPA receptors and the fibrinolytic response in multiple sclerosis lesions. Am J Pathol 166:1143-1151
101. Halangk W, Lerch MM, Brandt-Nedelev B, Roth W, Ruthenbuerger M, Reinheckel T, Domschke W, Lippert H, Peters C, Deussing J (2000) Role of cathepsin B in intracellular trypsinogen activation and the onset of acute pancreatitis. J Clin Invest 106:773-781
102. Hale LP, Greer PK, Trinh CT, Gottfried MR (2005) Treatment with oral bromelain decreases colonic inflammation in the IL-10-deficient murine model of inflammatory bowel disease. Clin Immunol 116:135-142
103. Harkness KA, Adamson P, Sussman JD, Davies-Jones GA, Greenwood J, Woodroofe MN (2000) Dexamethasone regulation of matrix metalloproteinase expression in CNS vascular endothelium. Brain 123:698-709
104. Hassen GW, Feliberti J, Kesner L, Stracher A, Mokhtarian F (2006) A novel calpain inhibitor for the treatment of acute experimental autoimmune encephalomyelitis. J Neuroimmunol 180:135-146
105. Helfer B, Boswell BC, Finlay D, Cipres A, Vuori K, Bong Kang T, Wallach D, Dorfleutner A, Lahti JM, Flynn DC, Frisch SM (2006) Caspase-8 promotes cell motility and calpain activity under nonapoptotic conditions. Cancer Res 66:4273-4278
106. Hemmer B, Archelos JJ, Hartung H-P (2002) New concepts in the immunopathogenesis of multiple sclerosis. Nat Rev 3:291-301
107. Hewson AK, Smith T, Leonard JP, Cuzner ML (1995) Suppression of experimental allergic encephalomyelitis in the Lewis rat by the matrix metalloproteinase inhibitor Ro31-9790. Inflammation Res 44:345-349
108. Hibbs MS, Hasty KA, Seyer JM, Kang AH, Mainardi CL (1985) Biochemical and immunological characterization of the secreted forms of human neutrophil gelatinase. J Biol Chem 260:2493-2500
109. Hisahara S, Shoji S, Okano H, Miura M (1997) ICE/CED-3 family executes oligodendrocyte apoptosis by tumor necrosis factor. J Neurochem 69:10-20
110. Hosseini H, Andre P, Lefevre N, Viala L, Walzer T, Peschanski M, Lotteau V (2001) Protection against experimental autoimmune encephalomyelitis by a proteasome modulator. J Neuroimmunol 118:233-244
111. Howe CL, Adelson JD, Rodriguez M (2007) Absence of perforin expression confers axonal protection despite demyelination. Neurobiol Dis 25:354-359
112. Huang WX, Huang P, Hillert J (2004) Increased expression of caspase-1 and interleukin-18 in peripheral blood mononuclear cells in patients with multiple sclerosis. Mult Scler 10:482-487
113. Hundhausen C, Misztela D, Berkhout TA, Broadway N, Saftig P, Reiss K, Hartmann D, Fahrenholz F, Postina R, Matthews V, Kallen KJ, Rose-John S, Ludwig A (2003) The disintegrin-like metalloproteinase ADAM10 is involved in constitutive cleavage of CX3CL1 (fractalkine) and regulates CX3CL1-mediated cell-cell adhesion. Blood 102:1186-1195
114. Huovila AP, Turner AJ, Pelto-Huikko M, Karkkainen I, Ortiz RM (2005) Shedding light on ADAM metalloproteinases. Trends Biochem Sci 30:413-422
115. Ibrahim MZ, Reder AT, Lawand R, Takash W, Sallouh-Khatib S (1996) The mast cells of the multiple sclerosis brain. J Neuroimmunol 70:131-138
116. Imai C, Okamura A, Peng JF, Kitamura Y, Printz MP (2005) Interleukin-1beta enhanced action of kinins on extracellular matrix of spontaneous hypertensive rat cardiac fibroblasts. Clin Exp Hypertens 27:59-69
117. Inaba Y, Ichikawa M, Inoue A, Itoh M, Kyogashima M, Sekiguchi Y, Nakamura S, Komiyama A, Koh C (2001) Plasma thrombin-antithrombin III complex is associated with the severity of experimental autoimmune encephalomyelitis. J Neurol Sci 185:89-93
118. Inoue A, Koh CS, Shimada K, Yanagisawa N, Yoshimura K (1996) Suppression of cell-transferred experimental autoimmune encephalomyelitis in defibrinated Lewis rats. J Neuroimmunol 71:131-137
119. Inoue A, Koh CS, Yamazaki M, Yanagisawa N, Ishihara Y, Kim BS (1997) Fibrin deposition in the central nervous system correlates with the degree of Theiler's murine encephalomyelitis virus-induced demyelinating disease. J Neuroimmunol 77:185-194
120. Inuzuka T, Sato S, McIntyre LJ, Quarles RH (1984) Effects of trypsin and plasmin treatment of myelin on the myelin-associated glycoprotein and basic protein. J Neurochem 43:582-585
121. Ishihara H, Connolly AJ, Zeng D, Kahn ML, Zheng YW, Timmons C, Tram T, Coughlin SR (1997) Protease-activated receptor 3 is a second thrombin receptor in humans. Nature 386:502-506
122. Iwata A, Stys PK, Wolf JA, Chen XH, Taylor AG, Meaney DF, Smith DH (2004) Traumatic axonal injury induces proteolytic cleavage of the voltage-gated sodium channels modulated by tetrodotoxin and protease inhibitors. J Neurosci 24:4605-4613
123. Johnston JB, Zhang K, Silva C, Shalinsky DR, Conant K, Ni W, Corbett D, Yong VW, Power C (2001) HIV-1 Tat neurotoxicity is prevented by matrix metalloproteinase inhibitors. Ann Neurol 49:230-241
124. Junge CE, Lee CJ, Hubbard KB, Ahoabin A, Olson JJ, Hepler JR, Brat DJ, Traynelis SF (2004) Protease-activated receptor-1 in human brain: localization and functional expression in astrocytes. Exp Neurol 1888:94-103
125. Jurewicz A, Matysiak M, Tybor K, Kilianek L, Raine CS, Selmaj K (2005) Tumour necrosis factor-induced death of adult human oligodendrocytes is mediated by apoptosis inducing factor. Brain 128:2675-2688
126. Karabudak R, Kurne A, Guc D, Sengelen M, Canpinar H, Kansu E (2004) Effect of interferon beta-1a on serum matrix metalloproteinase-9 (MMP-9) and tissue inhibitor of matrix metalloproteinase (TIMP-1) in relapsing remitting multiple sclerosis patients. One year follow-up results. J Neurol 251:279-283
127. Kastenbauer S, Koedel U, Wick M, Kieseier BC, Hartung HP, Pfister HW (2003) CSF and serum levels of soluble fractalkine (CX3CL1) in inflammatory diseases of the nervous system. J Neuroimmunol 137:210-217
128. Kawagoe J, Takizawa T, Matsumoto J, Tamiya M, Meek SE, Smith AJ, Hunter GD, Plevin R, Saito N, Kanke T, Fujii M, Wada Y (2002) Effect of protease-activated receptor-2 deficiency on allergic dermatitis in the mouse ear. Jpn J Pharmacol 88:77-84
129. Kermode AG, Thompson AJ, Tofts P, MacManus DG, Kendall BE, Kingsley DP, Moseley IF, Rudge P, McDonald WI (1990) Breakdown of the blood-brain barrier precedes symptoms and other MRI signs of new lesions in multiple sclerosis. Pathogenetic and clinical implications. Brain 113:1477-1489
130. Kieseier BC, Kiefer R, Clements JM, Miller K, Wells GM, Schweitzer T, Gearing AJ, Hartung HP (1998) Matrix metalloproteinase-9 and -7 are regulated in experimental autoimmune encephalomyelitis. Brain 121:159-166
131. Kieseier BC, Pischel H, Neuen-Jacob E, Tourtellotte WW, Hartung HP (2003) ADAM-10 and ADAM-17 in the inflamed human CNS. Glia 42:398-405
132. Klein G, Kullich W, Schnitker J, Schwann H (2006) Efficacy and tolerance of an oral enzyme combination in painful osteoarthritis of the hip. A double-blind, randomised study comparing oral enzymes with non-steroidal anti-inflammatory drugs. Clin Exp Rheumatol 24:25-30
133. Koh CS, Gausas J, Paterson PY (1993) Neurovascular permeability and fibrin deposition in the central neuraxis of Lewis rats with cell-transferred experimental allergic encephalomyelitis in relationship to clinical and histopathological features of the disease. J Neuroimmunol 47:141-145
134. Koli K, Saharinen J, Hyytiainen M, Penttinen C, Keski-Oja J (2001) Latency, activation, and binding proteins of TGF-beta. Microsc Res Tech 52:354-362
135. Krem MM, Di Cera E (2002) Evolution of enzyme cascades from embryonic development to blood coagulation. Trends Biochem Sci 27:67-74
136. Kruger PG (2001) Mast cells and multiple sclerosis: a quantitative analysis. Neuropathol Appl Neurobiol 27:275-280
137. Kruidenier L, MacDonald TT, Collins JE, Pender SL, Sanderson IR (2006) Myofibroblast matrix metalloproteinases activate the neutrophil chemoattractant CXCL7 from intestinal epithelial cells. Gastroenterology 130:127-136
138. Kuida K, Lippke JA, Ku G, Harding MW, Livingston DJ, Su MS, Flavell RA (1995) Altered cytokine export and apoptosis in mice deficient in interleukin-1 beta converting enzyme. Science 267:2000-2003
139. Kwon EE, Prineas JW (1994) Blood-brain barrier abnormalities in longstanding multiple sclerosis lesions. An immunohistochemical study. J Neuropathol Exp Neurol 53:625-636
140. Lacraz S, Nicod L, Galve-de Rochemonteix B, Baumberger C, Dayer JM, Welgus HG (1992) Suppression of metalloproteinase biosynthesis in human alveolar macrophages by interleukin-4. J Clin Invest 90:382-388
141. Ladiwala U, Lachance C, Simoneau SJ, Bhakar A, Barker PA, Antel JP (1998) p75 neurotrophin receptor expression on adult human oligodendrocytes: signaling without cell death in response to NGF. J Neurosci 18:1297-1304
142. Larsen PH, DaSilva AG, Conant K, Yong VW (2006) Myelin formation during development of the CNS is delayed in matrix metalloproteinase-9 and -12 null mice. J Neurosci 26:2207-2214
143. Lauber K, Bohn E, Krober SM, Xiao YJ, Blumenthal SG, Lindemann RK, Marini P, Wiedig C, Zobywalski A, Baksh S, Xu Y, Autenrieth IB, Schulze-Osthoff K, Belka C, Stuhler G, Wesselborg S (2003) Apoptotic cells induce migration of phagocytes via caspase-3-mediated release of a lipid attraction signal. Cell 113:717-730
144. Law MJ, Martenson RE, Deibler GE (1984) Cleavage of rabbit myelin basic protein by thrombin. J Neurochem 42:559-568
145. Lee KR, Drury I, Vitarbo E, Hoff JT (1997) Seizures induced by intracerebral injection of thrombin: a model of intracerebral hemorrhage. J Neurosurg 87:73-78
146. Leppert D, Waubant E, Burk MR, Oksenberg JR, Hauser SL (1996) Interferon beta-1b inhibits gelatinase secretion and in vitro migration of human T cells: a possible mechanism for treatment efficacy in MS. Ann Neurol 40:846-852
147. Lerch MM, Halangk W, Kruger B (2000) The role of cysteine proteases in intracellular pancreatic serine protease activation. Adv Exp Med Biol 477:403-411
148. Li P, Allen H, Banerjee S, Franklin S, Herzog L, Johnston C, McDowell J, Paskind M, Rodman L, Salfeld J et al (1995) Mice deficient in IL-1 beta-converting enzyme are defective in production of mature IL-1 beta and resistant to endotoxic shock. Cell 80:401-411
149. Lijnen HR, Silence J, Lemmens G, Frederix L, Collen D (1998) Regulation of gelatinase activity in mice with targeted inactivation of components of the plasminogen/plasmin system. Thromb Haemost 79:1171-1176
150. Lim SY, Tennant GM, Kennedy S, Wainwright CL, Kane KA (2006) Activation of mouse protease-activated receptor-2 induces lymphocyte adhesion and generation of reactive oxygen species. Br J Pharmacol 149:591-599
151. Lindberg RLP, De Groot CJA, Montagne L, Freitag P, van der Valk P, Kappos L, Leppert D (2001) The expression profile of matrix metalloproteinases (MMPs) and their inhibitors (TIMPs) in lesions and normal appearing white matter of multiple sclerosis. Brain 124:1743-1753
152. Liu Z, Zhou X, Shapiro SD, Shipley JM, Twining SS, Diaz LA, Senior RM, Werb Z (2000) The serpin alpha1-proteinase inhibitor is a critical substrate for gelatinase B/MMP-9 in vivo. Cell 102:647-655
153. Loher F, Bauer C, Landauer N, Schmall K, Siegmund B, Lehr HA, Dauer M, Schoenharting M, Endres S, Eigler A (2004) The interleukin-1 beta-converting enzyme inhibitor pralnacasan reduces dextran sulfate sodium-induced murine colitis and T helper 1 T-cell activation. J Pharmacol Exp Ther 308:583-590
154. Lopez-Otin C, Overall CM (2002) Protease degradomics: a new challenge for proteomics. Nat Rev Mol Cell Biol 3:509-519
155. Lu W, Bhasin M, Tsirka SE (2002) Involvement of tissue plasminogen activator in onset and effector phases of experimental allergic encephalomyelitis. J Neurosci 22:10781-10789
156. Lucchinetti C, Bruck W, Parisi J, Scheithauer B, Rodriguez M, Lassmann H (2000) Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination. Ann Neurol 47:707-717
157. Luo LY, Jiang W (2006) Inhibition profiles of human tissue kallikreins by serine protease inhibitors. Biol Chem 387:813-816
158. Ma J, Tanaka KF, Yamada G, Ikenaka K (2006) Induced expression of cathepsins and cystatin C in a murine model of demyelination. Neurochem Res 32:311-320
159. Macfelda K, Weiss TW, Kaun C, Breuss JM, Zorn G, Oberndorfer U, Voegele-Kadletz M, Huber-Beckmann R, Ullrich R, Binder BR, Losert UM, Maurer G, Pacher R, Huber K, Wojta J (2002) Plasminogen activator inhibitor 1 expression is regulated by the inflammatory mediators interleukin-1alpha, tumor necrosis factor-alpha, transforming growth factor-beta and oncostatin M in human cardiac myocytes. J Mol Cell Cardiol 34:1681-1691
160. Maciejewski-Lenoir D, Chen S, Feng L, Maki R, Bacon KB (1999) Characterization of fractalkine in rat brain cells: migratory and activation signals for CX3CR-1-expressing microglia. J Immunol 163:1628-1635
161. Madri JA, Graesser D, Haas T (1996) The roles of adhesion molecules and
162. Maeda A, Sobel RA (1996) Matrix metalloproteinases in the normal human central nervous system, microglia nodules, and multiple sclerosis lesions. J Neuropathol Exp Neurol 55:300-309
163. Malamud V, Vaaknin A, Abramsky O, Mor M, Burgess LE, Ben-Yehudah A, Lorberboum-Galski H (2003) Tryptase activates peripheral blood mononuclear cells causing synthesis and release of TNF-a, IL-6 and IL-1B: possible relevance to multiple sclerosis. J Neuroimmunology 138:115-122
164. Mandler RN, Dencoff JD, Midani F, Ford CC, Ahmed W, Rosenberg GA (2001) Matrix metalloproteinases and tissue inhibitors of metalloproteinases in cerebrospinal fluid differ in multiple sclerosis and Devic's neuromyelitis optica. Brain 124:493-498
165. Manhart N, Akomeah R, Bergmeister H, Spittler A, Ploner M, Roth E (2002) Administration of proteolytic enzymes bromelain and trypsin diminish the number of CD4+ cells and the interferon-gamma response in Peyer's patches and spleen in endotoxemic balb/c mice. Cell Immunol 215:113-119
166. Marks N, Grynbaum A, Levine S (1977) Proteolytic enzymes in ordinary, hyperacute, monocytic and passive transfer forms of experimental allergic encephalomyelitis. Brain Res 123:147-157
167. Martinon F, Tschopp J (2007) Inflammatory caspases and inflammasomes: master switches of inflammation. Cell Death Differ 14:10-22
168. Mason JL, Suzuki K, Chaplin DD, Matsushima GK (2001) Interleukin-1beta promotes repair of the CNS. J Neurosci 21:7046-7052
169. McCawley LJ, Matrisian LM (2001) Matrix metalloproteinases: they're not just for matrix anymore! Curr Opin Cell Biol 13:534-540
170. McQuibban GA, Butler GS, Gong JH, Bendall L, Power C, Clark-Lewis I, Overall CM (2001) Matrix metalloproteinase activity inactivates the CXC chemokine stromal cell-derived factor-1. J Biol Chem 276:43503-43508
171. McQuibban GA, Gong JH, Wong JP, Wallace JL, Clark-Lewis I, Overall CM (2002) Matrix metalloproteinase processing of monocyte chemoattractant proteins generates CC chemokine receptor antagonists with anti-inflammatory properties in vivo. Blood 100:1160-1167
172. Mead RJ, Singhrao SK, Neal JW, Lassmann H, Morgan BP (2002) The membrane attack complex of complement causes severe demyelination associated with acute axonal injury. J Immunol 168:458-465
173. Ming X, Li W, Maeda Y, Blumberg B, Raval S, Cook SD, Dowling PC (2002) Caspase-1 expression in multiple sclerosis plaques and cultured glial cells. J Neurol Sci 197:9-18
174. Mitsui S, Okui A, Uemura H, Mizuno T, Yamada T, Yamamura Y, Yamaguchi N (2002) Decreased cerebrospinal fluid levels of neurosin (KLK6), an aging-related protease, as a possible new risk factor for Alzheimer's disease. Ann NY Acad Sci 977:216-223
175. Moscarello MA, Mastronardi FG, Wood DD (2006) The role of citrullinated proteins suggests a novel mechanism in the pathogenesis of multiple sclerosis. Neurochem Res 32:251-256
176. Murray PD, McGavern DB, Lin X, Njenga MK, Leibowitz J, Pease LR, Rodriguez M (1998) Perforin-dependent neurologic injury in a viral model of multiple sclerosis. J Neurosci 18:7306-7314
177. Musse AA, Boggs JM, Harauz G (2006) Deimination of membrane-bound myelin basic protein in multiple sclerosis exposes an immunodominant epitope. Proc Natl Acad Sci USA 103:4422-4427
178. Nadiri A, Wolinski MK, Saleh M (2006) The inflammatory caspases: key players in the host response to pathogenic invasion and sepsis. J Immunol 177:4239-4245
179. Nagai A, Terashima M, Harada T, Shimode K, Takeuchi H, Murakawa Y, Nagasaki M, Nakano A, Kobayashi S (2003) Cathepsin B and H activities and cystatin C concentrations in cerebrospinal fluid from patients with leptomeningeal metastasis. Clin Chim Acta 329:53-60
180. Nagano O, Murakami D, Hartmann D, De Strooper B, Saftig P, Iwatsubo T, Nakajima M, Shinohara M, Saya H (2004) Cell-matrix interaction via CD44 is independently regulated by different metalloproteinases activated in response to extracellular Ca(2+) influx and PKC activation. J Cell Biol 165:893-902
181. Nagase H, Woessner JF Jr (1999) Matrix metalloproteinases. J Biol Chem 274:21491-1494
182. Nakagawa TY, Brissette WH, Lira PD, Griffiths RJ, Petrushova N, Stock J, McNeish JD, Eastman SE, Howard ED, Clarke SR, Rosloniec EF, Elliott EA, Rudensky AY (1999) Impaired invariant chain degradation and antigen presentation and diminished collagen-induced arthritis in cathepsin S null mice. Immunity 10:207-217
183. Nam RK, Diamandis EP, Toi A, Trachtenberg J, Magklara A, Scorilas A, Papnastasiou PA, Jewett MA, Narod SA (2000) Serum human glandular kallikrein-2 protease levels predict the presence of prostate cancer among men with elevated prostate-specific antigen. J Clin Oncol 18:1036-1042
184. Nauta AJ, Daha MR, Tijsma O, van de Water B, Tedesco F, Roos A (2002) The membrane attack complex of complement induces caspase activation and apoptosis. Eur J Immunol 32:783-792
185. Neuhaus O, Strasser-Fuchs S, Fazekas F, Kieseier BC, Niederwieser G, Hartung HP, Archelos JJ (2002) Statins as immunomodulators: comparison with interferon-beta 1b in MS. Neurology 59:990-997
186. Neumann H (2003) Molecular mechanisms of axonal damage in inflammatory central nervous system diseases. Curr Opin Neurol 16:267-273
187. Newman TA, Woolley ST, Hughes PM, Sibson NR, Anthony DC, Perry VH (2001) T-cell- and macrophage-mediated axon damage in the absence of a CNS-specific immune response: involvement of metalloproteinases. Brain 124:2203-214
188. Nicholson DW (1999) Caspase structure, proteolytic substrates, and function during apoptotic cell death. Cell Death Differ 6:1028-1042
189. Niclou SP, Suidan HS, Pavlik A, Vejsada R, Monard D (1998) Changes in the expression of protease-activated receptor 1 and protease nexin-1 mRNA during rat nervous system development and after nerve lesion. Eur J Neurosci 10:1590-1607
190. Niculescu T, Weerth S, Niculescu F, Cudrici C, Rus V, Raine CS, Shin ML, Rus H (2004) Effects of complement C5 on apoptosis in experimental autoimmune encephalomyelitis. J Immunol 172:5702-5706
191. Noorbakhsh F, Tsutsui S, Vergnolle N, Boven LA, Shariat N, Vodjgani M, Warren KG, Andrade-Gordon P, Hollenberg MD, Power C (2006) Proteinase-activated receptor 2 modulates neuroinflammation in experimental autoimmune encephalomyelitis and multiple sclerosis. J Exp Med 203:425-435
192. Norga K, Paemen L, Masure S, Dillen C, Heremans H, Billiau A, Carton H, Cuzner L, Olsson T, Van Damme J, Opdenakker G (1995) Prevention of acute autoimmune encephalomyelitis and abrogation of relapses in murine models of multiple sclerosis by the protease inhibitor D-penicillamine. Inflammation Res 44:529-534
193. Norton WT, Cammer W, Bloom BR, Gordon S (1978) Neutral proteinases secreted by macrophages degrade basic protein: a possible mechanism of inflammatory demyelination. Adv Exp Med Biol 100:365-381
194. Nygardas PT, Hinkkanen AE (2002) Up-regulation of MMP-8 and MMP-9 activity in the BALB/c mouse spinal cord correlates with the severity of experimental autoimmune encephalomyelitis. Clin Exp Immunol 128:245-254
195. Ogata Y, Enghild JJ, Nagase H (1992) Matrix metalloproteinase 3 (stromelysin) activates the precursor for the human matrix metalloproteinase 9. J Biol Chem 267:3581-3584
196. Oikonomopoulou K, Hansen KK, Saifeddine M, Tea I, Blaber M, Blaber SI, Scarisbrick I, Andrade-Gordone P, Cottrellf GS, Bunnett NW, Diamandis EP, Hollenberg MD (2006) Proteinase-activated receptors (PARs): Targets for kallikrein signalling. J Biol Chem 281:32095-32112
197. Opdenakker G, Dillen C, Fiten P, Martens E, Van Aelst I, Van den Steen PE, Nelissen I, Starckx S, Descamps FJ, Hu J, Piccard H, Van Damme J, Wormald MR, Rudd PM, Dwek RA (2006) Remnant epitopes, autoimmunity and glycosylation. Biochim Biophys Acta 1760:610-615
198. Overall CM, Kleifeld O (2006) Towards third generation matrix metalloproteinase inhibitors for cancer therapy. Br J Cancer 94:941-946
199. Paczek L, Kropiewnicka EH, Bartlomiejczyk I, Gradowska L, Heidland A, Wood G (2000) Systemic proteolytic enzyme treatment diminishes urinary interleukin 6 in diabetic patients. Nephron 84:194-195
200. Paemen L, Olsson T, Soderstron M, Damme JV, Openakker G (1994) Evaluation of gelatinases and IL-6 in the cerebrospinal fluid of patients with optic neuritis, multiple sclerosis and other inflammatory neurological diseases. Eur J Neurosci 1:55-63
201. Pagenstecher A, Stalder AK, Kincaid CL, Shapiro SD, Campbell IL (1998) Differential expression of matrix metalloproteinase and tissue inhibitor of matrix metalloproteinase genes in the mouse central nervous system in normal and inflammatory states. Am J Pathol 152:729-741
202. Palombella VJ, Conner EM, Fuseler JW, Destree A, Davis JM, Laroux FS, Wolf RE, Huang J, Brand S, Elliott PJ, Lazarus D, McCormack T, Parent L, Stein R, Adams J, Grisham MB (1998) Role of the proteasome and NF-kappaB in streptococcal cell wall-induced polyarthritis. Proc Natl Acad Sci USA 95:15671-15676
203. Parathath SR, Parathath S, Tsirka SE (2006) Nitric oxide mediates neurodegeneration and breakdown of the blood-brain barrier in tPA-dependent excitotoxic injury in mice. J Cell Sci 119:339-349
204. Paterson PY (1976) Experimental allergic encephalomyelitis: role of fibrin deposition in immunopathogenesis of inflammation in rats. Fed Proc 35:2428-2434
205. Perraud F, Besnard F, Sensenbrenner M, Labourdette G (1987) Thrombin is a potent mitogen for rat astroblasts but not for oligodendroblasts and neuroblasts in primary culture. Int J Dev Neurosci 5:181-188
206. Peterson JW, Bo L, Mork S, Chang A, Trapp BD (2001) Transected neurites, apoptotic neurons, and reduced inflammation in cortical multiple sclerosis lesions. Ann Neurol 50:389-400
207. Phillips JB, Williams AJ, Adams J, Elliott PJ, Tortella FC (2000) Proteasome inhibitor PS519 reduces infarction and attenuates leukocyte infiltration in a rat model of focal cerebral ischemia. Stroke 31:1686-1693
208. Pike CJ, Vaughan PJ, Cunningham DD, Cotman CW (1996) Thrombin attenuates neuronal cell death and modulates astrocyte reactivity induced by beta-amyloid in vitro. J Neurochem 66:1374-1382
209. Pritzker LB, Joshi S, Gowan JJ, Harauz G, Moscarello MA (2000) Deimination of myelin basic protein. 1. Effect of deimination of arginyl residues of myelin basic protein on its structure and susceptibility to digestion by cathepsin D. Biochemistry 39:5374-5381
210. Proost P, Van Damme J, Opdenakker G (1993) Leukocyte gelatinase B cleavage releases encephalitogens from human myelin basic protein. Biochem Biophys Res Comm 192:1175-1781
211. Proost P, Struyf S, Schols D, Durinx C, Wuyts A, Lenaerts JP, De Clercq E, De Meester I, Van Damme J (1998) Processing by CD26/dipeptidyl-peptidase IV reduces the chemotactic and anti-HIV-1 activity of stromal-cell-derived factor-1alpha. FEBS Lett 432:73-76
212. Proost P, Schutyser E, Menten P, Struyf S, Wuyts A, Opdenakker G, Detheux M, Parmentier M, Durinx C, Lambeir AM, Neyts J, Liekens S, Maudgal PC, Billiau A, Van Damme J (2001) Amino-terminal truncation of CXCR3 agonists impairs receptor signaling and lymphocyte chemotaxis, while preserving antiangiogenic properties. Blood 98:3554-3561
213. Puente SS, Sanchez LM, Overall CM, Lopez-Otin C (2003) Human and mouse proteases: a comparative genomic approach. Nat Rev Genet 4:544-558
214. Ramwani JJ, Epand RM, Moscarello MA (1989) Secondary structure of charge isomers of myelin basic protein before and after phosphorylation. Biochemistry 28:6538-6543
215. Rao RM, Betz TV, Lamont DJ, Kim MB, Shaw SK, Froio RM, Baleux F, Arenzana-Seisdedos F, Alon R, Luscinskas FW (2004) Elastase release by transmigrating neutrophils deactivates endothelial-bound SDF-1alpha and attenuates subsequent T lymphocyte transendothelial migration. J Exp Med 200:713-724
216. Richter R, Bistrian R, Escher S, Forssmann WG, Vakili J, Henschler R, Spodsberg N, Frimpong-Boateng A, Forssmann U (2005) Quantum proteolytic activation of chemokine CCL15 by neutrophil granulocytes modulates mononuclear cell adhesiveness. J Immunol 175:1599-1608
217. Riese RJ, Mitchell RN, Villadangos JA, Shi GP, Palmer JT, Karp ER, De Sanctis GT, Ploegh HL, Chapman HA (1998) Cathepsin S activity regulates antigen presentation and immunity. J Clin Invest 101:2351-2363
218. Rivera S, Tremblay E, Timsit S, Canals O, Ben-Ari Y, Khrestchatisky M (1997) Tissue inhibitor of metalloproteinases-1 (TIMP-1) is differentially induced in neurons and astrocytes after seizures: evidence for developmental, immediate early gene, and lesion response. J Neurosci 17:4223-4235
219. Rosenberg GA, Estrada EY, Dencoff JE, Stetler-Stevenson WG (1995) TNF-alpha-induced gelatinase beta causes delayed opening of the blood-brain barrier: an expanded therapeutic window. Brain Res 703:151-155
220. Rosenberg GA, Dencoff JE, Correa NJ, Reiners M, Ford CC (1996) Effect of steroids on CSF matrix metalloproteinases in multiple sclerosis: relation to blood-brain barrier injury. Neurology 46:1626-1632
221. Rosenberg GA, Estrada EY, Mobashery S (2007) Effect of synthetic matrix metalloproteinase inhibitors on lipopolysaccharide-induced blood-brain barrier opening in rodents: Differences in response based on strains and solvents. Brain Res 1133:186-192
222. Rozniecki JJ, Hauser SL, Stein M, Lincoln R, Theoharides TC (1995) Elevated mast cell tryptase in cerebrospinal fluid of multiple sclerosis patients. Ann Neurol 37:63-66
223. Rudolphi K, Gerwin N, Verzijl N, van der Kraan P, van den Berg W (2003) Pralnacasan, an inhibitor of interleukin-1beta converting enzyme, reduces joint damage in two murine models of osteoarthritis. Osteoarthritis Cartilage 11:738-746
224. Rus H, Cudrici C, Niculescu F (2006) C5b-9 complement complex in autoimmune demyelination: dual role in neuroinflammation and neuroprotection. Adv Exp Med Biol 586:139-151
225. Saatman KE, Abai B, Grosvenor A, Vorwerk CK, Smith DH, Meaney DF (2003) Traumatic axonal injury results in biphasic calpain activation and retrograde transport impairment in mice. J Cereb Blood Flow Metab 23:34-42
226. Saleh M, Vaillancourt JP, Graham RK, Huyck M, Srinivasula SM, Alnemri ES, Steinberg MH, Nolan V, Baldwin CT, Hotchkiss RS, Buchman TG, Zehnbauer BA, Hayden MR, Farrer LA, Roy S, Nicholson DW (2004) Differential modulation of endotoxin responsiveness by human caspase-12 polymorphisms. Nature 429:75-79
227. Salmena L, Lemmers B, Hakem A, Matysiak-Zablocki E, Murakami K, Au PY, Berry DM, Tamblyn L, Shehabeldin A, Migon E, Wakeham A, Bouchard D, Yeh WC, McGlade JC, Ohashi PS, Hakem R (2003) Essential role for caspase 8 in T-cell homeostasis and T-cell-mediated immunity. Genes Dev 17:883-895
228. Sanz MJ, Hickey MJ, Johnston B, McCafferty DM, Raharjo E, Huang PL, Kubes P (2001) Neuronal nitric oxide synthase (NOS) regulates leukocyte-endothelial cell interactions in endothelial NOS deficient mice. Br J Pharmacol 134:305-312
229. Scarisbrick IA, Blaber SI, Lucchinetti CF, Genain CP, Blaber M, Rodriguez M (2002) Activity of a newly identified serine protease in CNS demyelination. Brain 125:1283-1296
230. Scarisbrick IA, Blaber SI, Tingling JT, Rodriguez M, Blaber M, Christophi GP (2006) Potential scope of action of tissue kallikreins in CNS immune-mediated disease. J Neuroimmunology 178: 167-176
231. Schaecher K, Rocchini A, Dinkins J, Matzelle DD, Banik NL (2002) Calpain expression and infiltration of activated T cells in experimental allergic encephalomyelitis over time: increased calpain activity begins with onset of disease. J Neuroimmunol 129:1-9
232. Schiemann F, Grimm TA, Hoch J, Gross R, Lindner B, Petersen F, Bulfone-Paus S, Brandt E (2006) Mast cells and neutrophils proteolytically activate chemokine precursor CTAP-III and are subject to counterregulation by PF-4 through inhibition of chymase and cathepsin G. Blood 107:2234-2242
233. Schmitz J, Owyang A, Oldham E, Song Y, Murphy E, McClanahan TK, Zurawski G, Moshrefi M, Qin J, Li X, Gorman DM, Bazan JF, Kastelein RA (2005) IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines. Immunity 23:479-490
234. Schonbeck U, Mach F, Libby P (1998) Generation of biologically active IL-1 beta by matrix metalloproteinases: a novel caspase-1-independent pathway of IL-1 beta processing. J Immunol 161:3340-3346
235. Secor VH, Secor WE, Gutekunst CA, Brown MA (2000) Mast cells are essential for early onset and severe disease in a murine model of multiple sclerosis. J Exp Med 191:813-822
236. Seeds NW, Williams BL, Bickford PC (1995) Tissue plasminogen activator induction in Purkinje neurons after cerebellar motor learning. Science 270:1992-1994
237. Seguin R, Biernacki K, Rotondo RL, Prat A, Antel JP (2003) Regulation and functional effects of monocyte migration across human brain-derived endothelial cells. J Neuropathol Exp Neurol 62:412-419
238. Seidel B, Keilhoff G, Reinheckel T, Wolf G (1998) Differentially expressed genes in hippocampal cell cultures in response to an excitotoxic insult by quinolinic acid. Brain Res Mol Brain Res 60:296-300
239. Seifert T, Kieseier BC, Ropele S, Strasser-Fuchs S, Quehenberger F, Fazekas F, Hartung HP (2002) TACE mRNA expression in peripheral mononuclear cells precedes new lesions on MRI in multiple sclerosis. Mult Scler 8:447-451
240. Sharma V, Delgado M, Ganea D (2006) VIP protects Th2 cells by downregulating granzyme B expression. Ann N Y Acad Sci 1070:540-544
241. Shields DC, Banik NL (1998) Upregulation of calpain activity and expression in experimental allergic encephalomyelitis: a putative role for calpain in demyelination. Brain Res 794:68-74
242. Shields DC, Schaecher KE, Saido TC, Banik NL (1999) A putative mechanism of demyelination in multiple sclerosis by a proteolytic enzyme, calpain. Proc Natl Acad Sci USA 96:11486-11491
243. Shipley JM, Wesselschmidt RL, Kobayashi DK, Ley TJ, Shapiro SD (1996) Metalloelastase is required for macrophage-mediated proteolysis and matrix invasion in mice. Proc Natl Acad Sci U S A 93:3942-3946
244. Siegel RM, Chan FK, Chun HJ, Lenardo MJ (2000) The multifaceted role of Fas signaling in immune cell homeostasis and autoimmunity. Nat Immunol 1:469-474
245. Siger-Zajdel M, Selmaj K (2001) Magnetisation transfer ratio analysis of normal appearing white matter in patients with familial and sporadic multiple sclerosis. J Neurol Neurosurg Psychiatry 71:752-756
246. Sim RB, Tsiftsoglou SA (2004) Proteases of the complement system. Biochem Soc Trans 32:21-27
247. Smalley DM, Ley K (2005) L-selectin: mechanisms and physiological significance of ectodomain cleavage. J Cell Mol Med 9:255-266
248. Smith ME, van der Maesen K, Somera FP (1998) Macrophage and microglial responses to cytokines in vitro: phagocytic activity, proteolytic enzyme release, and free radical production. J Neurosci Res 54:68-78
249. Soane L, Cho HJ, Niculescu F, Rus H, Shin ML (2001) C5b-9 terminal complement complex protects oligodendrocytes from death by regulating Bad through phosphatidylinositol 3-kinase/Akt pathway. J Immunol 167:2305-2311
250. Stack JH, Beaumont K, Larsen PD, Straley KS, Henkel GW, Randle JC, Hoffman HM (2005) IL-converting enzyme/caspase-1 inhibitor VX-765 blocks the hypersensitive response to an inflammatory stimulus in monocytes from familial cold autoinflammatory syndrome patients. J Immunol 175:2630-2634
251. Starckx S, Van den Steen PE, Verbeek R, van Noort JM, Opdenakker G (2003) A novel rationale for inhibition of gelatinase B in multiple sclerosis: MMP-9 destroys alpha B-crystallin and generates a promiscuous T cell epitope. J Neuroimmunol 141:47-57
252. Sternlicht MD, Werb Z (2001) How matrix metalloproteinases regulate cell behavior. Annu Rev Cell Dev Biol 17:463-516
253. Storch MK, Stefferl A, Brehm U, Weissert R, Wallstrom E, Kerschensteiner M, Olsson T, Linington C, Lassmann H (1998) Autoimmunity to myelin oligodendrocyte glycoprotein in rats mimics the spectrum of multiple sclerosis pathology. Brain Pathol 8:681-694
254. Strukova SM (2001) Thrombin as a regulator of inflammation and reparative processes in tissues. Biochemistry (Mosc) 66:8-18
255. Struyf S, Schutyser E, Gouwy M, Gijsbers K, Proost P, Benoit Y, Opdenakker G, Van Damme J, Laureys G (2003) PARC/CCL18 is a plasma CC chemokine with increased levels in childhood acute lymphoblastic leukemia. Am J Pathol 163:2065-2075
256. Stuve O, Dooley NP, Uhm JH, Antel JP, Francis GS, Williams G, Yong VW (1996) Interferon beta-1b decreases the migration of T lymphocytes in vitro: effects on matrix metalloproteinase-9. Ann Neurol 40:853-863
257. Tan HK, Heywood D, Ralph GS, Bienemann A, Baker AH, Uney JB (2003) Tissue inhibitor of metalloproteinase 1 inhibits excitotoxic cell death in neurons. Mol Cell Neurosci 22:98-106
258. Targoni OS, Tary-Lehmann M, Lehmann PV (1999) Prevention of murine EAE by oral hydrolytic enzyme treatment. J Autoimmun 12:191-198
259. Tarui T, Mazar AP, Cines DB, Takada Y (2001) Urokinase-type plasminogen activator receptor (CD87) is a ligand for integrins and mediates cell-cell interaction. J Biol Chem 276:3983-3990
260. Tedgui A, Mallat Z (2006) Cytokines in atherosclerosis: pathogenic and regulatory pathways. Physiol Rev 86:515-581
261. Teesalu T, Hinkkanen AE, Vaheri A (2001) Coordinated induction of extracellular proteolysis systems during experimental autoimmune encephalomyelitis in mice. Am J Pathol 159:2227-2237
262. Terayama R, Bando Y, Yamada M, Yoshida S (2005) Involvement of neuropsin in the pathogenesis of experimental autoimmune encephalomyelits. Glia 52:108-118
263. Thornberry NA, Bull HG, Calaycay JR, Chapman KT, Howard AD, Kostura MJ, Miller DK, Molineaux SM, Weidner JR, Aunins J et al (1992) A novel heterodimeric cysteine protease is required for interleukin-1 beta processing in monocytes. Nature 356:768-774
264. Tocco G, Musleh W, Sakhi S, Schreiber SS, Baudry M, Pasinetti GM (1997) Complement and glutamate neurotoxicity. Genotypic influences of C5 in a mouse model of hippocampal neurodegeneration. Mol Chem Neuropathol 31:289-300
265. Toft-Hansen H, Nuttall RK, Edwards DR, Owens T (2004) Key metalloproteinases are expressed by specific cell types in experimental autoimmune encephalomyelitis. J Immunol 173:5209-5218
266. Trapp BD, Peterson J, Ransohoff RM, Rudick R, Mork S, Bo L (1998) Axonal transection in the lesions of multiple sclerosis. N Engl J Med 338:278-285
267. Trojano M, Avolio C, Liuzzi GM, Ruggieri M, Defazio G, Liguori M, Santacroce MP, Paolicelli D, Giuliani F, Riccio P, Livrea P (1999) Changes of serum ICAM-1 and MMP-9 induced by IFNbeta-1b treatment in relapsing-remitting MS. Neurology 153:1402-1408
268. Tsirka SE, Gualandris A, Amaral DG, Strickland S (1995) Excitotoxin-induced neuronal degeneration and seizure are mediated by tissue plasminogen activator. Nature 377:340-344
269. Tsirka SE, Bugge TH, Degen JL, Strickland S (1997) Neuronal death in the central nervous system demonstrates a non-fibrin substrate for plasmin. Proc Natl Acad Sci USA 94:9779-9781
270. Tsirka SE, Rogove AD, Bugge TH, Degan JL, Strickland S (1997) An extracellular proteolytic cascade promotes neuronal degeneration in the mouse hippocampus. J Neurosci 15:543-552
271. Tsubata T, Takahashi K (1989) Limited proteolysis of bovine myelin basic protein by calcium-dependent proteinase from bovine spinal cord. J Biochem (Tokyo) 105:23-28
272. Uchida A, Oka Y, Aoyama M, Suzukim S, Yokoi T, Katano H, Mase M, Tada T, Asai K, Yamada K (2004) Expression of myelencephalon-specific protease in transient middle cerebral artery occlusion model of rat brain. Mol Brain Res 126:129-136
273. Ulrich R, Baumgartner W, Gerhauser I, Seeliger F, Haist V, Deschl U, Alldinger S (2006) MMP-12, MMP-3, and TIMP-1 are markedly upregulated in chronic demyelinating Theiler murine encephalomyelitis. J Neuropath Exp Neurol 65:783-793
274. Vakili J, Standker L, Detheux M, Vassart G, Forssmann WG, Parmentier M (2001) Urokinase plasminogen activator and plasmin efficiently convert hemofiltrate CC chemokine 1 into its active. J Immunol 167:3406-3413
275. Van den Steen PE, Husson SJ, Proost P, Van Damme J, Opdenakker G (2003) Carboxyterminal cleavage of the chemokines MIG and IP-10 by gelatinase B and neutrophil collagenase. Biochem Biophys Res Commun 310:889-896
276. Van Den Steen PE, Wuyts A, Husson SJ, Proost P, Van Damme J, Opdenakker G (2003) Gelatinase B/MMP-9 and neutrophil collagenase/MMP-8 process the chemokines human GCP-2/CXCL6, ENA-78/CXCL5 and mouse GCP-2/LIX and modulate their physiological activities. Eur J Biochem 270:3739-3749
277. van Noort JM, van Sechel AC, Bajramovic JJ, el Ouagmiri M, Polman CH, Lassmann H, Ravid R (1995) The small heat-shock protein alpha B-crystallin as candidate autoantigen in multiple sclerosis. Nature 375:798-801
278. Vanderlugt CL, Rahbe SM, Elliott PJ, Dal Canto MC, Miller SD (2000) Treatment of established relapsing experimental autoimmune encephalomyelitis with the proteasome inhibitor PS-519. J Autoimmun 14:205-211.
279. Vergelli M, Hemmer B, Muraro PA, Tranquill L, Biddison WE, Sarin A, McFarland HF, Martin R (1997) Human autoreactive CD4+ T cell clones use perforin- or Fas/Fas ligand-mediated pathways for target cell lysis. J Immunol 158:2756-2761
280. Vergnolle N, Wallace JL, Bunnett NW, Hollenberg MD (2001) Protease-activated receptors in inflammation, neuronal signaling and pain. Trends Pharmacol Sci 22:146-152
281. Vos CM, van Haastert ES, de Groot CJ, van der Valk P, de Vries HE (2003) Matrix metalloproteinase-12 is expressed in phagocytotic macrophages in active multiple sclerosis lesions. J Neuroimmunol 138:106-114
282. Wakefield AJ, More LJ, Difford J, McLaughlin JE (1994) Immunohistochemical study of vascular injury in acute multiple sclerosis. J Clin Pathol 47:129-133
283. Waltz DA, Natkin LR, Fujita RM, Wei Y, Chapman HA (1997) Plasmin and plasminogen activator inhibitor type 1 promote cellular motility by regulating the interaction between the urokinase receptor and vitronectin. J Clin Invest 100:58-67
284. Wang T, Allie R, Conant K, Haughey N, Turchan-Chelowo J, Hahn K, Rosen A, Steiner J, Keswani S, Jones M, Calabresi PA, Nath A (2006) Granzyme B mediates neurotoxicity through a G-protein-coupled receptor. FASEB J 20:1209-1211
285. Ward PA (1967) A plasmin-split fragment of C'3 as a new chemotactic factor. J Exp Med 126:189-206
286. Waubant E, Goodkin DE, Gee L, Bacchetti P, Sloan R, Stewart T, Andersson P-B, Stabler G, Miller K (1999) Serum MMP-9 and TIMP-1 levels are related to MRI activity in relapsing multiple sclerosis. Neurolology 53:1397-1401
287. Waubant E, Goodkin D, Bostrom A, Bacchetti P, Hietpas J, Lindberg R, Leppert D (2003) IFNbeta lowers MMP-9/TIMP-1 ratio, which predicts new enhancing lesions in patients with SPMS. Neurology 60:52-57
288. Weaver A, Goncalves da Silva A, Nuttall RK, Edwards DR, Shapiro SD, Rivest S, Yong VW (2005) An elevated matrix metalloproteinase (MMP) in an animal model of multiple sclerosis is protective by affecting Th1/Th2 polarization. FASEB J 19:1668-1670
289. Weinstein JR, Gold SJ, Cunningham DD, Gall CM (1995) Cellular localization of thrombin receptor mRNA in rat brain: expression by mesencephalic dopaminergic neurons and codistribution with prothrombin mRNA. J Neurosci 15:2906-2919
290. Wiedow O, Meyer-Hoffert U (2005) Neutrophil serine proteases: potential key regulators of cell signalling during inflammation. J Intern Med 257:319-328
291. Williams KR, Williams ND, Konigsberg W, Yu RK (1986) Acidic lipids enhance cathepsin D cleavage of the myelin basic protein. J Neurosci Res 15:137-145
292. Wood DD, Bilbao JM, O'Connors P, Moscarello MA (1996) Acute multiple sclerosis (Marburg type) is associated with developmentally immature myelin basic protein. Ann Neurol 40:18-24
293. Xia M, Leppert D, Hauser SL, Sreedharan SP, Nelson PJ, Krensky AM, Goetzl EJ (1996) Stimulus specificity of matrix metalloproteinase dependence of human T cell migration through a model basement membrane. J Immunol 156:160-167
294. Xue M, Del Bigio MR (2001) Acute tissue damage after injections of thrombin and plasmin into rat striatum. Stroke 32:2164-2169
295. Xue M, Hollenberg MD, Yong VW (2006) Combination of thrombin and matrix metalloproteinase-9 exacerbates neurotoxicity in cell culture and intracerebral hemorrhage in mice. J Neurosci 26:10281-10291
296. Yang YH, Hall P, Little CB, Fosang AJ, Milenkovski G, Santos L, Xue J, Tipping P, Morand EF (2005) Reduction of arthritis severity in protease-activated receptor-deficient mice. Arthritis Rheum 52:1325-1332
297. Yepes M, Sandkvist M, Wong MK, Coleman TA, Smith E, Cohan SL, Lawrence DA (2000) Neuroserpin reduces cerebral infarct volume and protects neurons from ischemia-induced apoptosis. Blood 96:569-776
298. Yong VW (2005) Metalloproteinases: mediators of pathology and regeneration in the CNS. Nat Rev Neurosci 6:931-944
299. Yushchenko M, Mader M, Elitok E, Bitsch A, Dressel A, Tumani H, Bogumil T, Kitze B, Poser S, Weber F (2003) Interferon-beta-1 b decreased matrix metalloproteinase-9 serum levels in primary progressive multiple sclerosis. J Neurol 250:1224-1228
300. Zabel BA, Zuniga L, Ohyama T, Allen SJ, Cichy J, Handel TM, Butcher EC (2006) Chemoattractants, extracellular proteases, and the integrated host defense response. Exp Hematol 34:1021-1032
301. Zajicek JP, Wing M, Scolding NJ, Compston DA (1992) Interactions between oligodendrocytes and microglia. A major role for complement and tumour necrosis factor in oligodendrocyte adherence and killing. Brain 115:1611-1631
302. Zarghooni M, Soosaipillai A, Grass L, Scorilas A, Mirazimi N, Diamandis EP (2002) Decreased concentration of human kallikrein 6 in brain extracts of Alzheimer's disease patients. Clin Biochem 35:225-231
303. Zeine R, Pon R, Ladiwala U, Antel JP, Filion LG, Freedman MS (1998) Mechanism of gammadelta T cell-induced human oligodendrocyte cytotoxicity: relevance to multiple sclerosis. J Neuroimmunol 87:49-61
304. Zhang WH, Wang X, Narayanan M, Zhang Y, Huo C, Reed JC, Friedlander RM (2003) Fundamental role of the Rip2/caspase-1 pathway in hypoxia and ischemia-induced neuronal cell death. Proc Natl Acad Sci USA 100:16012-16017